HPV – Information for Parents

The School Aged Immunisation Team will be attending all schools to deliver the HPV vaccination to Year 8 students from January 2023.

Please speak to your child about the vaccination then complete the consent to either accept or decline the vaccination as soon as possible.

All parents whose children attend school have now received an email with information about the vaccination and a consent link. This was sent via email by your child’s school on behalf of HCRG Care Group School Aged Immunisation Team.

You can complete the consent or decline the vaccination using the link below:

Consent form for B&NES, Swindon and Wiltshire schools.

You can view the school codes list below:

School code list

If your child is Electively Home Educated you can find your unique code here

If your child is not registered at, or attending a school for any reason they can be vaccinated at a local community clinic. Please complete a consent form and contact our immunisation Single Point of Access on 0300 247 0082 to make an appointment.

HPV is a large group of related viruses, each group is given a number and is called a ‘type’.

The viruses can infect the deepest layer of the skin of the upper respiratory and genital tracts through skin to skin contact.

There are over 40 types of HPV that affect the genital area, and the high risk types 16 and 18 can lead to cancer of the cervix, anus, genitals and oropharyngeal (head and neck) areas.

Lower risk types 6 and 11 can cause genital warts

Nearly all sexually active people are infected with HPV at some point in their lives.

Infection usually occurs after sexual debut and almost 40% of women are infected within 2 years.

70% of new high risk infections with clear within a year

90% of new infections clear within 2 years.

Vaccination has been shown to be highly effective and well tolerated.

Infections of HPV types 16 and 18, the main cancer causing types, has reduced by 86% in 16-21 year old women in England

In 2018, 10 years after vaccination was introduced, no HPV 16 and/or 18 infections were detected in 16 -1 8 year olds, indicating the programme has succeeded in delivering both direct and indirect protection

The rates of cervical cancer have reduced by 90% in women in their 20s compared to an unvaccinated population

Genital wart diagnoses among 15-17 yr old girls has decreased by 85% and by 80% in heterosexual boys

It is over 99% effective at preventing pre-cancerous lesions

It is 99% effective at preventing genital warts

Clinical trials indicate that it can prevent anal cell changes caused by persistent infection and genital warts

HPV vaccination has been established through rigorous testing in clinical trials, followed by extensive use with more than 500 million doses given across the world.

No concerns about the safety of the vaccination have been raised, and no link between the vaccination and the development of a range of chronic illnesses has been supported.

This is supported by the independent health bodies and authorities worldwide:

The Joint Committee on Vaccinations and Immunisations, Medicines Health Regulatory Agency, World Health Organisation Global Advisory Committee on Vaccine Safety

European Medicines Agency

US Centre for Disease Control and Prevention

Health Canada